APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Induced Side Effects Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Opioid Induced Side Effects Treatment Market Outlook and Growth Opportunities 2026

2 January 2026193 pages

Choose your research edition.

Industry ResearchOpioid Induced Side Effects Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Induced Side Effects Treatment Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Opioid Induced Side Effects Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Induced Side Effects Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Induced Side Effects Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Opioid Induced Side Effects Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Opioid Induced Side Effects Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Induced Side Effects Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Induced Side Effects Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Opioid Induced Side Effects Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Opioid Induced Side Effects Treatment market include AstraZeneca, SLA Pharma, Shionogi, Progenics Pharmaceuticals, Cubist Pharmaceuticals and AIKO Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Opioid Induced Side Effects Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Induced Side Effects Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Induced Side Effects Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Opioid Induced Side Effects Treatment market.

Opioid Induced Side Effects Treatment Segment by Company

AstraZeneca

SLA Pharma

Shionogi

Progenics Pharmaceuticals

Cubist Pharmaceuticals

AIKO Biotechnology

Opioid Induced Side Effects Treatment Segment by Type

Risperidone

Methylphenidate

Cetirizine

Other

Opioid Induced Side Effects Treatment Segment by Application

Drug Overdose Treatment

Pain Treatment

Other

Opioid Induced Side Effects Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Opioid Induced Side Effects Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Opioid Induced Side Effects Treatment key companies, revenue, market share, and recent developments.

3. To split the Opioid Induced Side Effects Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Opioid Induced Side Effects Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioid Induced Side Effects Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Opioid Induced Side Effects Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Induced Side Effects Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Induced Side Effects Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Induced Side Effects Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid Induced Side Effects Treatment industry.

Chapter 3: Detailed analysis of Opioid Induced Side Effects Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Opioid Induced Side Effects Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Opioid Induced Side Effects Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioid Induced Side Effects Treatment Industry Trends Table 2. Opioid Induced Side Effects Treatment Industry Drivers Table 3. Opioid Induced Side Effects Treatment Industry Opportunities and Challenges Table 4. Opioid Induced Side Effects Treatment Industry Restraints Table 5. Global Opioid Induced Side Effects Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioid Induced Side Effects Treatment Revenue Share by Company (2021-2026) Table 7. Global Opioid Induced Side Effects Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Opioid Induced Side Effects Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Opioid Induced Side Effects Treatment Company, Product Type & Application Table 10. Global Opioid Induced Side Effects Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Opioid Induced Side Effects Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Risperidone Table 15. Significant Companies of Methylphenidate Table 16. Significant Companies of Cetirizine Table 17. Significant Companies of Other Table 18. Global Opioid Induced Side Effects Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Opioid Induced Side Effects Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Opioid Induced Side Effects Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Opioid Induced Side Effects Treatment Sales Value Share by Type (2021-2026) Table 22. Global Opioid Induced Side Effects Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Drug Overdose Treatment Table 24. Significant Companies of Pain Treatment Table 25. Significant Companies of Other Table 26. Global Opioid Induced Side Effects Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Opioid Induced Side Effects Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Opioid Induced Side Effects Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Opioid Induced Side Effects Treatment Sales Value Share by Application (2021-2026) Table 30. Global Opioid Induced Side Effects Treatment Sales Value Share by Application (2027-2032) Table 31. Global Opioid Induced Side Effects Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Opioid Induced Side Effects Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Opioid Induced Side Effects Treatment Sales Value Share by Region (2021-2026) Table 34. Global Opioid Induced Side Effects Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Opioid Induced Side Effects Treatment Sales Value Share by Region (2027-2032) Table 36. Global Opioid Induced Side Effects Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Opioid Induced Side Effects Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Opioid Induced Side Effects Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global Opioid Induced Side Effects Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Opioid Induced Side Effects Treatment Sales Value Market Share by Country (2027-2032) Table 41. AstraZeneca Company Information Table 42. AstraZeneca Business Overview Table 43. AstraZeneca Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. AstraZeneca Opioid Induced Side Effects Treatment Product Portfolio Table 45. AstraZeneca Recent Development Table 46. SLA Pharma Company Information Table 47. SLA Pharma Business Overview Table 48. SLA Pharma Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. SLA Pharma Opioid Induced Side Effects Treatment Product Portfolio Table 50. SLA Pharma Recent Development Table 51. Shionogi Company Information Table 52. Shionogi Business Overview Table 53. Shionogi Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Shionogi Opioid Induced Side Effects Treatment Product Portfolio Table 55. Shionogi Recent Development Table 56. Progenics Pharmaceuticals Company Information Table 57. Progenics Pharmaceuticals Business Overview Table 58. Progenics Pharmaceuticals Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Progenics Pharmaceuticals Opioid Induced Side Effects Treatment Product Portfolio Table 60. Progenics Pharmaceuticals Recent Development Table 61. Cubist Pharmaceuticals Company Information Table 62. Cubist Pharmaceuticals Business Overview Table 63. Cubist Pharmaceuticals Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Cubist Pharmaceuticals Opioid Induced Side Effects Treatment Product Portfolio Table 65. Cubist Pharmaceuticals Recent Development Table 66. AIKO Biotechnology Company Information Table 67. AIKO Biotechnology Business Overview Table 68. AIKO Biotechnology Opioid Induced Side Effects Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AIKO Biotechnology Opioid Induced Side Effects Treatment Product Portfolio Table 70. AIKO Biotechnology Recent Development Table 71. Research Programs/Design for This Report Table 72. Authors List of This Report Table 73. Secondary Sources Table 74. Primary Sources List of Figures Figure 1. Opioid Induced Side Effects Treatment Product Image Figure 2. Global Opioid Induced Side Effects Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Induced Side Effects Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Induced Side Effects Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Risperidone Image Figure 8. Methylphenidate Image Figure 9. Cetirizine Image Figure 10. Other Image Figure 11. Global Opioid Induced Side Effects Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Opioid Induced Side Effects Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Opioid Induced Side Effects Treatment Sales Value Share by Type (2021-2032) Figure 14. Drug Overdose Treatment Image Figure 15. Pain Treatment Image Figure 16. Other Image Figure 17. Global Opioid Induced Side Effects Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Opioid Induced Side Effects Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Opioid Induced Side Effects Treatment Sales Value Share by Application (2021-2032) Figure 20. Global Opioid Induced Side Effects Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Opioid Induced Side Effects Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Opioid Induced Side Effects Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America Opioid Induced Side Effects Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Opioid Induced Side Effects Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Opioid Induced Side Effects Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Opioid Induced Side Effects Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Opioid Induced Side Effects Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Opioid Induced Side Effects Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America Opioid Induced Side Effects Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Opioid Induced Side Effects Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Opioid Induced Side Effects Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Risperidone
  • Methylphenidate
  • Cetirizine
  • Other
Applications
  • Drug Overdose Treatment
  • Pain Treatment
  • Other
Companies covered
  • AstraZeneca
  • SLA Pharma
  • Shionogi
  • Progenics Pharmaceuticals
  • Cubist Pharmaceuticals
  • AIKO Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioid Induced Side Effects Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioid Induced Side Effects Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Opioid Induced Side Effects Treatment Market Dynamics
  1. 2.1 Opioid Induced Side Effects Treatment Industry Trends
  2. 2.2 Opioid Induced Side Effects Treatment Industry Drivers
  3. 2.3 Opioid Induced Side Effects Treatment Industry Opportunities and Challenges
  4. 2.4 Opioid Induced Side Effects Treatment Industry Restraints
3 Opioid Induced Side Effects Treatment Market by Company
  1. 3.1 Global Opioid Induced Side Effects Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Opioid Induced Side Effects Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Opioid Induced Side Effects Treatment Company Ranking (2024-2026)
  4. 3.4 Global Opioid Induced Side Effects Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Opioid Induced Side Effects Treatment Company Product Type and Application
  6. 3.6 Global Opioid Induced Side Effects Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Opioid Induced Side Effects Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Opioid Induced Side Effects Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Opioid Induced Side Effects Treatment Market by Type
  1. 4.1 Opioid Induced Side Effects Treatment Type Introduction
  2. 4.1.1 Risperidone
  3. 4.1.2 Methylphenidate
  4. 4.1.3 Cetirizine
  5. 4.1.4 Other
  6. 4.2 Global Opioid Induced Side Effects Treatment Sales Value by Type
  7. 4.2.1 Global Opioid Induced Side Effects Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioid Induced Side Effects Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Opioid Induced Side Effects Treatment Sales Value Share by Type (2021-2032)
5 Opioid Induced Side Effects Treatment Market by Application
  1. 5.1 Opioid Induced Side Effects Treatment Application Introduction
  2. 5.1.1 Drug Overdose Treatment
  3. 5.1.2 Pain Treatment
  4. 5.1.3 Other
  5. 5.2 Global Opioid Induced Side Effects Treatment Sales Value by Application
  6. 5.2.1 Global Opioid Induced Side Effects Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Induced Side Effects Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Opioid Induced Side Effects Treatment Sales Value Share by Application (2021-2032)
6 Opioid Induced Side Effects Treatment Regional Value Analysis
  1. 6.1 Global Opioid Induced Side Effects Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Induced Side Effects Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Opioid Induced Side Effects Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Opioid Induced Side Effects Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioid Induced Side Effects Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Opioid Induced Side Effects Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Opioid Induced Side Effects Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Opioid Induced Side Effects Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Opioid Induced Side Effects Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Opioid Induced Side Effects Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Opioid Induced Side Effects Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Opioid Induced Side Effects Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Opioid Induced Side Effects Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Opioid Induced Side Effects Treatment Sales Value Share by Country, 2025 VS 2032
7 Opioid Induced Side Effects Treatment Country-level Value Analysis
  1. 7.1 Global Opioid Induced Side Effects Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioid Induced Side Effects Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Opioid Induced Side Effects Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Opioid Induced Side Effects Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Opioid Induced Side Effects Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Opioid Induced Side Effects Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Opioid Induced Side Effects Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Opioid Induced Side Effects Treatment Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 SLA Pharma
  8. 8.2.1 SLA Pharma Company Information
  9. 8.2.2 SLA Pharma Business Overview
  10. 8.2.3 SLA Pharma Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 SLA Pharma Opioid Induced Side Effects Treatment Product Portfolio
  12. 8.2.5 SLA Pharma Recent Developments
  13. 8.3 Shionogi
  14. 8.3.1 Shionogi Company Information
  15. 8.3.2 Shionogi Business Overview
  16. 8.3.3 Shionogi Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shionogi Opioid Induced Side Effects Treatment Product Portfolio
  18. 8.3.5 Shionogi Recent Developments
  19. 8.4 Progenics Pharmaceuticals
  20. 8.4.1 Progenics Pharmaceuticals Company Information
  21. 8.4.2 Progenics Pharmaceuticals Business Overview
  22. 8.4.3 Progenics Pharmaceuticals Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Progenics Pharmaceuticals Opioid Induced Side Effects Treatment Product Portfolio
  24. 8.4.5 Progenics Pharmaceuticals Recent Developments
  25. 8.5 Cubist Pharmaceuticals
  26. 8.5.1 Cubist Pharmaceuticals Company Information
  27. 8.5.2 Cubist Pharmaceuticals Business Overview
  28. 8.5.3 Cubist Pharmaceuticals Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cubist Pharmaceuticals Opioid Induced Side Effects Treatment Product Portfolio
  30. 8.5.5 Cubist Pharmaceuticals Recent Developments
  31. 8.6 AIKO Biotechnology
  32. 8.6.1 AIKO Biotechnology Company Information
  33. 8.6.2 AIKO Biotechnology Business Overview
  34. 8.6.3 AIKO Biotechnology Opioid Induced Side Effects Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AIKO Biotechnology Opioid Induced Side Effects Treatment Product Portfolio
  36. 8.6.5 AIKO Biotechnology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst